Back to results
US 2020/0347146 A1Published application
Anti-cd73 anti-pd-l1 bispecific antibodies
AssigneeI-Mab Biopharma US Limited
InventorsZhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang, Qiumei Yang
Life of this patent
Estimating the term…
Abstract
Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.
Claims28
A bispecific antibody comprising an anti-CD73 portion and an anti-PD-L1 portion,
- wherein the anti-CD73 portion has binding specificity to a human CD73 protein and comprises a heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:1, a CDRH2 comprising the amino acid sequence of SEQ ID NO:2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:3, and a light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:4, a CDRL2 comprising the amino acid sequence of SEQ ID NO:5, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:6, and
- wherein the anti-PD-L1 portion has binding specificity to a human PD-L1 protein and comprises a heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:7, a CDRH2 comprising the amino acid sequence of SEQ ID NO:8, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:9, and a light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:10, a CDRL2 comprising the amino acid sequence of SEQ ID NO:11, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:12.
(canceled)
(canceled)
(canceled)
28-32. (canceled)
Dependencies are inferred from the claim text.